Shionogi and NEC collaborate on hepatitis B vaccine
High unmet need in the area of hepatitis B therapies will see companies share responsibilities to develop the vaccine
Read Moreby John Pinching | Apr 19, 2022 | News | 0
High unmet need in the area of hepatitis B therapies will see companies share responsibilities to develop the vaccine
Read Moreby Lucy Parsons | Jan 14, 2021 | News | 0
Companies will collaborate on a combination therapy study
Read Moreby Anna Smith | Nov 14, 2019 | News | 0
The impact of chronic hepatitis B treatment on hepatocellular carcinoma incidence was evaluated in a long-term analysis of the Gilead drug.
Read Moreby Anna Smith | Aug 28, 2019 | News | 0
GSK is now responsible for all development, regulatory and commercialisation activities and costs.
Read Moreby Selina McKee | Nov 13, 2017 | News | 0
The US Food and Drug Administration is allowing onto the market the first new hepatitis B vaccine in more than 25 years with the approval of Dynavax’ Heplisav-B.
Read Moreby Selina McKee | Jan 12, 2017 | News | 0
Patients with chronic hepatitis B in Europe have gained the first new treatment option in nearly 10 years following the approval of Gilead’s Vemlidy.
Read Moreby Selina McKee | Nov 15, 2016 | News | 0
Shares in US group Dynavax Technologies fell through the floor after US regulators refused to approve its flagship hepatitis B vaccine Heplisav-B.
Read Moreby Selina McKee | Aug 4, 2016 | News | 0
Roche has pulled the plug on its collaboration with Inovio after stepping away from the development of the second candidate, the hepatitis B DNA immunotherapy INO-1800.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
